670 related articles for article (PubMed ID: 23715562)
1. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
[TBL] [Abstract][Full Text] [Related]
3. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
5. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
[TBL] [Abstract][Full Text] [Related]
6. Prediction of response to anticancer immunotherapy using gene signatures.
Wang E; Bedognetti D; Marincola FM
J Clin Oncol; 2013 Jul; 31(19):2369-71. PubMed ID: 23715576
[No Abstract] [Full Text] [Related]
7. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
Saiag P; Gutzmer R; Ascierto PA; Maio M; Grob JJ; Murawa P; Dreno B; Ross M; Weber J; Hauschild A; Rutkowski P; Testori A; Levchenko E; Enk A; Misery L; Vanden Abeele C; Vojtek I; Peeters O; Brichard VG; Therasse P
Ann Oncol; 2016 Oct; 27(10):1947-53. PubMed ID: 27502712
[TBL] [Abstract][Full Text] [Related]
8. [Molecular biology of lung cancer series].
Hiret S; Senellart H; Bennouna J
Rev Mal Respir; 2010 Oct; 27(8):954-8. PubMed ID: 20965409
[TBL] [Abstract][Full Text] [Related]
9. MAGE A3 antigen-specific cancer immunotherapeutic.
Peled N; Oton AB; Hirsch FR; Bunn P
Immunotherapy; 2009 Jan; 1(1):19-25. PubMed ID: 20635969
[TBL] [Abstract][Full Text] [Related]
10. Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis.
Jang SJ; Soria JC; Wang L; Hassan KA; Morice RC; Walsh GL; Hong WK; Mao L
Cancer Res; 2001 Nov; 61(21):7959-63. PubMed ID: 11691819
[TBL] [Abstract][Full Text] [Related]
11. Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.
Pujol JL; Vansteenkiste JF; De Pas TM; Atanackovic D; Reck M; Thomeer M; Douillard JY; Fasola G; Potter V; Taylor P; Bosquée L; Scheubel R; Jarnjak S; Debois M; de Sousa Alves P; Louahed J; Brichard VG; Lehmann FF
J Thorac Oncol; 2015 Oct; 10(10):1458-67. PubMed ID: 26309191
[TBL] [Abstract][Full Text] [Related]
12. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.
Bolli M; Kocher T; Adamina M; Guller U; Dalquen P; Haas P; Mirlacher M; Gambazzi F; Harder F; Heberer M; Sauter G; Spagnoli GC
Ann Surg; 2002 Dec; 236(6):785-93; discussion 793. PubMed ID: 12454517
[TBL] [Abstract][Full Text] [Related]
13. Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer.
Adam V; Wauters I; Vansteenkiste J
Expert Opin Biol Ther; 2014 Mar; 14(3):365-76. PubMed ID: 24456101
[TBL] [Abstract][Full Text] [Related]
14. A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.
Slingluff CL; Petroni GR; Olson WC; Smolkin ME; Chianese-Bullock KA; Mauldin IS; Smith KT; Deacon DH; Varhegyi NE; Donnelly SB; Reed CM; Scott K; Galeassi NV; Grosh WW
Cancer Immunol Immunother; 2016 Jan; 65(1):25-36. PubMed ID: 26581199
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma.
McQuade JL; Homsi J; Torres-Cabala CA; Bassett R; Popuri RM; James ML; Vence LM; Hwu WJ
BMC Cancer; 2018 Dec; 18(1):1274. PubMed ID: 30567529
[TBL] [Abstract][Full Text] [Related]
16. Characterization of melanoma-associated antigen-a genes family differential expression in non-small-cell lung cancers.
Karimi S; Mohammadi F; Porabdollah M; Mohajerani SA; Khodadad K; Nadji SA
Clin Lung Cancer; 2012 May; 13(3):214-9. PubMed ID: 22138038
[TBL] [Abstract][Full Text] [Related]
17. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.
Tyagi P; Mirakhur B
Clin Lung Cancer; 2009 Sep; 10(5):371-4. PubMed ID: 19808198
[TBL] [Abstract][Full Text] [Related]
18. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178.
Bettinotti MP; Panelli MC; Ruppe E; Mocellin S; Phan GQ; White DE; Marincola FM
Int J Cancer; 2003 Jun; 105(2):210-6. PubMed ID: 12673681
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients.
Melloni G; Ferreri AJ; Russo V; Gattinoni L; Arrigoni G; Ceresoli GL; Zannini P; Traversari C
Oncol Rep; 2004 Jul; 12(1):145-51. PubMed ID: 15201976
[TBL] [Abstract][Full Text] [Related]
20. Expression of melanoma-antigen-A (MAGE-A) in disseminated tumor cells in regional lymph nodes of patients with operable non-small cell lung cancer.
Dango S; Wang XT; Gold M; Cucuruz B; Klein CA; Passlick B; Sienel W
Lung Cancer; 2010 Mar; 67(3):290-5. PubMed ID: 19467731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]